Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDMONASDAQ:CMRXNASDAQ:KMPHNASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$6.53▼$12.51$799.18M1.391.35 million shs3.07 million shsCMRXChimerix$8.54$7.72$0.75▼$8.55$801.09M-0.172.27 million shsN/AKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsOCSOculis$17.00-5.8%$18.54$10.79▼$23.08$742.25M0.1943,922 shs63,796 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%+0.60%+82.94%CMRXChimerix0.00%0.00%+0.35%+115.66%+842.60%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%OCSOculis+0.89%-1.20%-8.28%-19.81%+50.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDMOAvid Bioservices0.714 of 5 stars1.00.00.04.50.61.70.6CMRXChimerix2.7886 of 5 stars1.04.00.04.12.12.50.6KMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOCSOculis2.035 of 5 stars3.53.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideCMRXChimerix 2.00Hold$8.53-0.08% DownsideKMPHZevra Therapeutics 0.00N/AN/AN/AOCSOculis 3.00Buy$30.2577.94% UpsideCurrent Analyst Ratings BreakdownLatest KMPH, CMRX, CDMO, and OCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/13/2025OCSOculisRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$37.00 ➝ $41.003/13/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/13/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $29.003/5/2025CMRXChimerixJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$10.00 ➝ $8.503/5/2025CMRXChimerixWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$7.00 ➝ $8.553/5/2025CMRXChimerixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$11.00 ➝ $8.552/18/2025CMRXChimerixWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$6.00 ➝ $7.002/18/2025CMRXChimerixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94KMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00OCSOculis$980K757.40N/AN/A$2.87 per share5.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%6/30/2025 (Estimated)CMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%4/29/2025 (Estimated)KMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/AOCSOculis-$98.92M-$2.31N/AN/AN/A-8,043.28%-71.31%-56.85%5/14/2025 (Estimated)Latest KMPH, CMRX, CDMO, and OCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025OCSOculis-$0.50N/AN/AN/AN/AN/A5/7/2025Q1 2025CMRXChimerix-$0.27N/AN/AN/AN/AN/A3/21/2025Q4 2024CMRXChimerix-$0.26-$0.25+$0.01-$0.25$0.31 million$0.06 million3/11/2025Q4 2024OCSOculis-$0.48-$0.76-$0.28-$0.76$0.21 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDMOAvid BioservicesN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDMOAvid Bioservices3.581.300.92CMRXChimerixN/A6.336.33KMPHZevra Therapeutics0.1410.1010.10OCSOculis0.014.024.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDMOAvid Bioservices97.16%CMRXChimerix45.42%KMPHZevra Therapeutics19.39%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipCDMOAvid Bioservices3.05%CMRXChimerix13.10%KMPHZevra Therapeutics1.10%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableCMRXChimerix9093.80 million78.15 millionOptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableOCSOculis243.66 millionN/ANot OptionableKMPH, CMRX, CDMO, and OCS HeadlinesRecent News About These CompaniesOculis Updates Share CapitalApril 25 at 4:00 PM | globenewswire.comOculis (NASDAQ:OCS) Stock Price Down 2.5% - What's Next?April 24 at 1:09 PM | marketbeat.comOculis (NASDAQ:OCS) Given Buy Rating at Chardan CapitalApril 20, 2025 | americanbankingnews.comOculis (NASDAQ:OCS) Price Target Raised to $32.00April 20, 2025 | americanbankingnews.comOculis (NASDAQ:OCS) Shares Gap Up Following Analyst UpgradeApril 19, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock PriceApril 19, 2025 | marketbeat.comOculis' (OCS) Buy Rating Reaffirmed at Chardan CapitalApril 19, 2025 | marketbeat.comOculis (NASDAQ:OCS) Shares Gap Up on Analyst UpgradeApril 19, 2025 | americanbankingnews.comOculis Holding (OCS) Receives a Buy from Bank of America SecuritiesApril 17, 2025 | markets.businessinsider.comOculis and EURETINA Announce the 2025 Ramin Tadayoni AwardApril 17, 2025 | globenewswire.comOculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D DayApril 15, 2025 | tipranks.comOculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline AssetsApril 15, 2025 | globenewswire.comOculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline AssetsApril 15, 2025 | globenewswire.comOculis Holding completes enrollment in both DIAMOND phase 3 clinical trials of OCS-01 in diabetic macular edemaApril 14, 2025 | pharmabiz.comOculis completes enrollment for pivotal DME treatment trialsApril 12, 2025 | uk.investing.comOculis completes enrolment in trials for diabetic macular oedema eye dropsApril 11, 2025 | finance.yahoo.comOculis completes enrollment in Phase 3 DIAMOND-1 and DIAMOND-2 trials for DME eye drop candidateApril 11, 2025 | ophthalmologytimes.comOculis Holding AG: Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular EdemaApril 11, 2025 | finanznachrichten.deOculis (NASDAQ:OCS) Stock Price Up 7.4% - Here's What HappenedApril 10, 2025 | marketbeat.comOculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular EdemaApril 10, 2025 | globenewswire.comOculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular EdemaApril 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKMPH, CMRX, CDMO, and OCS Company DescriptionsAvid Bioservices NASDAQ:CDMO$12.50 +0.02 (+0.12%) Closing price 02/5/2025Extended Trading$12.50 0.00 (0.00%) As of 02/5/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Chimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Zevra Therapeutics NASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.Oculis NASDAQ:OCS$17.00 -1.05 (-5.82%) Closing price 04:00 PM EasternExtended Trading$16.91 -0.09 (-0.53%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
